What Is Neoadjuvant Therapy for Breast Cancer?
When therapy is given before surgery, it is called neoadjuvant treatment or preoperative treatment. It was first used for patients with locally advanced breast cancer to shrink tumors that were too big to remove. Over time, doctors realized that this approach has other benefits.
Because the therapy shrinks the tumor, women can have breast-conserving surgery instead of complete removal (mastectomy).
Neoadjuvant therapy is used for:
-
Locally advanced breast cancer.
-
Inflammatory breast cancer.
-
Large tumors that doctors want to shrink before surgery.
-
Clinically node-negative patients with high-risk tumor features for whom chemotherapy would be needed anyway after surgery.
What Are the Benefits of Neoadjuvant Chemotherapy?
Neoadjuvant chemotherapy comes with various benefits.
Below are a few benefits
To begin, neoadjuvant chemotherapy is used to shrink tumors. Neoadjuvant chemotherapy reduces the size of a large tumor, making it easier for your surgeon to remove it during surgery.
This allows the doctor to see how the tumor responds to treatment and decide future treatment plans accordingly.
In some cases, neoadjuvant chemotherapy removes the tumor fully by destroying it before surgery, so you might not need surgery at all.
It helps in easy and quick recovery for those with small tumors needing a small incision.
Neoadjuvant chemotherapy treats the whole body, which helps eliminate tiny cancer cells that may have spread but are too small to detect with scans. This reduces the chances of cancer recurrence.
After neoadjuvant chemotherapy, the tumor is examined under a microscope; if no cancer cells are visible, it is considered a complete pathologic response. This often shows better long-term outcomes, making it an effective way to test how well new drugs work, and it helps doctors stop treatments early if they clearly are not helping.
If your cancer is not responding to the treatment, the doctor will adjust your dose or switch to another medicine, sparing you from unnecessary side effects, toxicity, and medications.
Another major advantage is that it supports personalized treatment. Because doctors can collect tumor samples before, during, and after chemotherapy, they can study how the cancer behaves in your body and how it changes over time. This allows doctors to identify which tumor features respond well or poorly.
The ultimate goal of this research is to develop treatment plans tailored to each individual, based on their specific biology and overall risk.
Why Is Neoadjuvant Therapy Done for Breast Cancer?
Advanced Breast Cancers: Neoadjuvant chemotherapy is a preoperative treatment that is often used for certain high-risk breast cancers. This includes tumors that are two centimeters or larger, as well as locally advanced breast cancers that our doctors may not be able to operate on at first.
Shrink the Large Tumors: One of the main roles of neoadjuvant therapy is to shrink the large tumors, making surgery possible or allowing patients to choose breast-conserving surgery instead of complete removal or mastectomy.
Monitor Treatment Response: Because the tumor remains in place during treatment, your doctor will closely monitor how well the cancer responds. If the tumor continues to grow, they stop the ineffective treatment and avoid it.
Improve Survival Rate: In estrogen receptor-negative cancers, some patients achieve a complete response, meaning no cancer is found at the time of surgery. These individuals tend to have much better survival rates than those with remaining disease.
Research and Studies: More recently, neoadjuvant therapy has also become a focus of research. It allows scientists to study how a tumor responds to treatment in the body and provides a short window before surgery to determine whether targeted therapies are hitting their intended pathways.
What Are the Procedures for Neoadjuvant Treatment?
If your treatment plan includes chemotherapy, it may be given before surgery sometimes, which is known as neoadjuvant chemotherapy.
The procedures for neoadjuvant chemotherapy depend on the treatment plan and may involve:
-
A full medical check-up is performed for you, during which the doctor reviews your medical history and may recommend tests such as mammograms, ultrasounds, MRI (magnetic resonance imaging), and biopsies to confirm the cancer type, size, spread, and hormone receptor status.
-
Depending on your cancer status, your doctor will recommend whether you need neoadjuvant chemotherapy, neoadjuvant hormone therapy, neoadjuvant targeted therapy, or a combination of these.
-
Once it is decided, chemotherapy is started and given in cycles for several weeks. Doctors will monitor the tumor and check the treatment response.
-
If the tumor shrinks, it makes a way for the doctors to go for a breast-conserving surgery instead of a mastectomy.
-
Imaging tests are repeated to check tumor shrinkage.
-
Blood tests are recommended to monitor your overall health.
-
If your tumor is not responding to neoadjuvant chemotherapy, the treatment plan will be changed to avoid unnecessary side effects.
-
If the neoadjuvant chemotherapy responds properly, then surgery is performed.
-
Post-surgery, based on the tumor shrinkage and removal, the doctor will advise radiation therapy, hormone or targeted therapy, additional chemotherapy, and long-term follow-up plans.
How Is Neoadjuvant Chemotherapy Done for HER2-Positive Breast Cancer?
For HER2 (human epidermal growth factor receptor 2)-positive breast cancer, neoadjuvant chemotherapy usually involves a combination of chemotherapy and HER2-targeted medicines. The most common targeted drugs used are Trastuzumab and Pertuzumab. Starting these treatments before surgery does not change overall survival compared to starting them after surgery; they are equally effective.
Trastuzumab: It is given through an IV (intravenous) infusion or injection every three weeks, typically for one full year. When used as neoadjuvant chemotherapy, part of the Trastuzumab course is given before surgery, and the rest after surgery. It is usually not given at the same time as anthracycline-based (drugs that belong to the class of highly effective medicines to kill cancer cells) chemotherapy because of the increased risk of heart-related side effects.
Pertuzumab: This is often given along with Trastuzumab in both neoadjuvant and adjuvant chemotherapy plans. This combination blocks HER2 receptors, increasing the likelihood of a strong response.
Emerging Options: Other HER2-targeted therapies are being studied for use before surgery. One such example is ado-trastuzumab emtansine (T-DM1). T-DM1 is already FDA (Food and Drug Administration)-approved for post-surgery treatment in early-stage HER2-positive breast cancer and is being explored as a possible neoadjuvant option.
Conclusion:
Neoadjuvant chemotherapy is used to shrink large and advanced tumors before surgery. Because of its ability to shrink tumors, it increases breast-conserving surgery rates and provides time insight into how a tumor responds to therapy. This allows doctors to decide on a personalized treatment plan and avoid unnecessary medication. Neoadjuvant therapy serves as an effective treatment and a powerful tool for precision medicine. If you want to know more about neoadjuvant therapy, talk to a specialist at iCliniq.
Key Takeaways:
-
Neoadjuvant chemotherapy is given before surgery to shrink the tumors and improve the surgical outcome.
-
It allows the doctors to monitor the tumor before, during, and after treatment.
-
It helps the doctors to switch therapies earlier if the tumor is not responding.
